Ginkgo Biloba: Standardized Botanical for Cognitive Support, Circulation & Tinnitus
⚡ 60-Second Summary
Ginkgo biloba leaf extract contains two primary active compound classes: flavone glycosides (quercetin, kaempferol, isorhamnetin — approximately 24% in standardized extracts) and terpene lactones (ginkgolides A, B, C, J — approximately 6% in standardized extracts). These compounds inhibit platelet-activating factor (PAF), improve cerebral blood flow (via prostaglandin and nitric oxide pathways), have antioxidant effects, and modulate neurotransmitter systems.
Best-evidenced applications: mild cognitive impairment and dementia-adjacent conditions (multiple European and Chinese RCTs with EGb 761), tinnitus reduction (meta-analyses confirm modest benefit), peripheral circulation improvement (claudication), and general cognitive support in older adults. Evidence is for standardized EGb 761 extract — generic 'ginkgo leaf powder' does not have the same evidence base.
Standardized extract (EGb 761) is crucial — most positive clinical evidence uses this specific standardized extract (24% flavone glycosides, 6% terpene lactones, <5 ppm ginkgolic acids). Generic leaf powder or non-standardized products lack equivalent clinical validation and variable potency.
What is Ginkgo Biloba?
Ginkgo biloba trees are 'living fossils' — essentially unchanged for 270 million years and the only living species in its plant division (Ginkgophyta). The trees can live over 1,000 years. Traditional Chinese medicine use began in the 11th century for breathing problems and bladder dysfunction. Modern pharmacological research began in Germany in the 1960s–70s.
EGb 761 (Tanakan in France, Tebonin in Germany) has been one of the most prescribed plant medicines in Europe for decades. The U.S. supplement market uses variable quality extracts.
Evidence-based benefits
Mild Cognitive Impairment and Dementia
A comprehensive meta-analysis (Tan et al., 2015, Journal of Alzheimer's Disease) of EGb 761 trials showed significant improvement in cognitive function and daily activities in patients with mild-to-moderate dementia. An earlier important German study (Kanowski et al., 1996, Pharmacopsychiatry) was a landmark placebo-controlled trial confirming EGb 761 benefits in dementia patients. The GEM trial (healthy older adults) showed no benefit for primary dementia prevention — the evidence is for mild-to-moderate cognitive impairment, not prevention.
Tinnitus
A systematic review and meta-analysis (Rejali et al., 2004) of EGb 761 for tinnitus showed significant improvement in tinnitus severity and handicap. Not curative but provides meaningful symptom relief for some. The cochlear circulation improvement mechanism is proposed.
Peripheral Artery Disease (Claudication)
Multiple RCTs confirm EGb 761 significantly increases pain-free walking distance in patients with peripheral artery disease. Meta-analysis shows approximately 50% greater improvement than placebo. This is one of the more consistently positive findings.
Healthy Adults
The evidence for cognitive enhancement in healthy young adults is mixed and much weaker than for older adults with mild cognitive impairment. The strongest effects are seen in populations with cognitive decline, not in optimizing normal cognition.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Form | Dose | Best For | Notes |
| EGb 761 Standardized Extract | 120–240 mg/day (often 40–80 mg 3x daily) | All clinical applications — the only form with robust RCT evidence | 24% flavone glycosides, 6% terpene lactones, <5 ppm ginkgolic acids |
| Other Standardized Extracts (24/6) | 120–240 mg/day | Alternative if ginkgolic acid limits are confirmed | Less clinical data than EGb 761 specifically; look for same standardization specs |
| Non-standardized 'Ginkgo Leaf Powder' | Not recommended — unpredictable potency | Not recommended | Without standardization, flavone glycoside and terpene lactone content is unpredictable |
How much should you take?
- 120 mg/day (40 mg 3x daily) to 240 mg/day EGb 761 for cognitive applications
- 480 mg/day has been studied for acute effects; standard daily dose is 120–240 mg
- Take with meals for best tolerability
- Minimum 6–8 weeks of consistent use to assess cognitive effects
EGb 761 or equivalent 24/6 standardized extracts are essential. The ginkgolic acid limit (<5 ppm) is also important — ginkgolic acids are contact allergens and cytotoxic at higher concentrations. Many products on the US market are not standardized to these specifications.
Safety and side effects
Common side effects
- Headache — most common adverse effect
- GI discomfort (nausea, diarrhea)
- Dizziness
- Bleeding risk — ginkgolides inhibit PAF (platelet-activating factor) and have anticoagulant effects
- Rare: seizures in people with history of seizure disorders
- Rare: spontaneous bleeding (case reports)
Serious risks
The most clinically significant safety concern is bleeding risk from PAF inhibition. People on anticoagulants (warfarin, aspirin, clopidogrel) or scheduled for surgery face meaningful bleeding risks with ginkgo supplementation. Stop ginkgo at least 36 hours before any surgical procedure.
Drug and nutrient interactions
- Warfarin and anticoagulants — additive bleeding risk; can increase INR significantly
- Antiplatelet drugs (aspirin, clopidogrel) — additive platelet inhibition; increased bleeding risk
- NSAIDs — additive bleeding risk
- Seizure medications — ginkgo has been reported to lower seizure threshold in some cases; monitor
- Diabetes medications — ginkgo may modulate insulin sensitivity; monitor glucose
- CYP2C19 substrates — ginkgo inhibits CYP2C19; may increase drug levels (omeprazole, diazepam)
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| Older adults (60+) with mild cognitive impairment or early dementia-adjacent conditions seeking botanical cognitive support | People scheduled for surgery within 1 week — significant bleeding risk; stop ginkgo |
| Individuals with tinnitus seeking evidence-based botanical support for symptom management | People taking warfarin or antiplatelet drugs without physician coordination — significant interaction |
| People with peripheral circulation problems or claudication wanting botanical support | People with seizure history — ginkgo may lower seizure threshold; consult neurologist |
| Adults interested in the most clinically researched botanical for age-related cognitive concerns | Pregnant or breastfeeding women — avoid; insufficient safety data |
Frequently asked questions
Does ginkgo actually improve memory?
The evidence is nuanced. For older adults with mild cognitive impairment or early dementia symptoms, EGb 761 improves scores on cognitive tests and activities of daily living in multiple RCTs. For healthy young adults seeking memory enhancement or nootropic effects, the evidence is much weaker and inconsistent. Ginkgo's effects are most reliably demonstrated in populations where cerebral circulation and neurotransmitter function are already declining.
Why is the standardized extract (EGb 761) so important?
Ginkgo leaf products vary enormously in flavone glycoside and terpene lactone content. Some 'ginkgo supplements' contain negligible amounts of active compounds. The clinical trial database is built almost entirely on EGb 761 — a specific extract with defined percentages of flavone glycosides (24%) and terpene lactones (6%) and strict ginkgolic acid limits (<5 ppm). Using non-standardized products is essentially taking an untested formulation, regardless of what generic ginkgo trials show.
Can ginkgo cause bleeding?
Yes, meaningfully so. Ginkgolides inhibit platelet-activating factor (PAF) — an important platelet aggregation trigger. This antiplatelet effect is clinically relevant: spontaneous bleeding cases (intracranial hemorrhage, subarachnoid hemorrhage, hyphema) have been reported in healthy people taking ginkgo. The risk increases significantly when combined with anticoagulants or antiplatelet medications. Always stop ginkgo before elective surgery or dental procedures.
Should I take ginkgo for dementia prevention?
The GEM trial (Ginkgo Evaluation of Memory study, 3,000 older adults, 6 years, EGb 761 240 mg/day) showed no benefit for dementia prevention in healthy older adults without cognitive impairment. Ginkgo is not established as a dementia prevention supplement. It may have value for individuals already showing mild cognitive impairment — the evidence is much stronger for that population than for prevention in cognitively normal individuals.
Related ingredients
Bacopa Monnieri
Complementary botanical cognitive support with memory consolidation mechanism.
Lion's Mane Mushroom
Complementary nootropic targeting NGF for neuronal health.
Phosphatidylserine
Cognitive phospholipid supplement with evidence for age-related cognitive support.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.